MILAN, ITALY -- (MARKET WIRE) -- December 21, 2006 -- Recordati announced that it has signed a non-exclusive agreement with sigma-tau, a leading Italian pharmaceutical company, for the marketing and sale in Italy of its new antihypertensive drug which combines lercanidipine and enalapril. The launch is expected to take place at the beginning of 2008 following approval in 2007. The new specialty, a fixed combination of lercanidipine and enalapril, was approved in Germany as announced on 27 July last. Germany will act as Reference Member State in the mutual recognition process for the rest of Europe which is expected to be completed during 2007.
